Adalimumab and Methotrexate Combination Therapy

ADALIMUMAB AND METHOTREXATE COMBINATION THERAPY

FIFE RHEUMATIC DISEASES UNIT

SHARED CARE BLOOD MONITORING FORM

PLEASE ASK YOUR PRACTICE NURSE TO COMPLETE THIS FORM AND THEN RETURN IT TO YOU TO KEEP WITH YOUR OWN RECORDS.

Name:

Abnormal trends in results should be noted in addition to the absolute values.

IF ANY PATIENT REPORTS NEW OR WORSENING BREATHLESSNESS ALWAYS CONTACT GP AND RHEUMATOLOGY DEPARTMENT

Guidelines for monitoring Adalimumab and Methotrexate combination therapy:

FBC/CRP: / Every 2 weeks for 3 months after starting Adalimumab and until 6 weeks after dose of Methotrexate is stable, monthly thereafter
Liver function: / Every 2 weeks until 6 weeks after dose of Methotrexate is stable, monthly thereafter
Renal function: / 6 –12 monthly if normal. Does not need to be done at every monitoring visit.
Date / HB / WCC
(> 3.5) / neutro
(>1.5) / Plts
(>100) / CRP / ALT
(<80) / creat / eGFR
General enquiries: 01592 648193
Date / HB / WCC
(> 3.5) / neutro
(>1.5) / Plts
(>100) / CRP / ALT
(<80) / creat / eGFR
General enquiries: 01592 648193

Updated August 2012 Version 1